Investors

News & Publications

Investors

Investor Relations

Corporate Profile

Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Price
Change
Volume
News Releases
September 26, 2018
NEW HAVEN, Conn. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade
March 20, 2018
NEW HAVEN, CT, March 20, 2018 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a company overview at the 17 th  Annual Needham
Events
No events are scheduled at this time.
Presentations
There are no presentations at this time.